View Older Stories View More Recent Stories
-
Strata Oncology Secures $26 Million in Series B Funding, Led by Pfizer and Merck
-
FogPharma Secures $66 Million Series B Financing
-
Gene Therapy Market, 2030
-
Form 13F-HR DEERFIELD MANAGEMENT For: Mar 31
-
Four found guilty in insider trading case linked to U.S. health agency
-
Adeptus Health Appoints Dr. Nirav R. Shah as Advisor in Residence
-
V-Wave Closes $70M Financing to Support Pivotal Study of its Heart Failure Therapy
-
Adeptus Health Appoints LeAnne Zumwalt to its Board of Directors
-
Neurotechnology Innovations Translator (NIT) Announces Funding of up to $50 Million in Portfolio Company, Sollis Therapeutics
-
CORRECTING and REPLACING Neurotechnology Innovations Translator (NIT) Announces Funding of up to $50 Million in Portfolio Company Sollis Therapeutics
-
Deerfield Leads Investment of up to $50 Million in Sollis Therapeutics' Innovative Solution for Sciatica Pain
-
Constellation Pharmaceuticals Announces $100 Million Financing
-
Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform
-
Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer
-
Washington insider's 'secret sauce' fueled NY hedge fund, U.S. says at trial
-
Deerfield Management and Vanderbilt University announce the launch of Ancora Innovation
-
Dracen Closes Financing to Advance Immunometabolism Pipeline
-
Deerfield Commits $36 Million to Advance Dracen's Novel Immuno-Metabolism Pipeline
-
DBV Technologies (DBVT) Prices 2.784M ADS Offering at $21.26/ADS as Part of Global Offering
-
DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
-
DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
-
Monsanto backs new company focused on gene editing, not GMOs
-
Monsanto and Pairwise Announce R&D Collaboration to Accelerate Innovation in Agriculture with Gene Editing
-
Pairwise Raises $25M Series A Financing to Accelerate Crop Innovation
-
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results
-
Bridge Medicines Accepts Novel Small Molecule Targeting Basal Cell Carcinoma As First Drug Candidate for Development
-
Generation Bio Announces $100 Million Series B Financing to Advance GeneWave™ Platform for Re-Dosable Gene Therapy
-
DFB Healthcare Acquisitions Corp. Closes $250 Million Initial Public Offering
-
Pharma Pricing Experts, Global Pricing Innovations (GPI), Expand Capabilities and Expertise with Two New Senior Appointments.
-
DFB Healthcare Acquisitions Corp. (DFBHU) Prices 25M Share IPO at $10/Sh
-
DFB Healthcare Acquisitions Corp. Announces Pricing of $250 Million Initial Public Offering
-
Form 13F-HR DEERFIELD MANAGEMENT For: Dec 31
-
Broad Institute and Deerfield Management Announce the Advancement of Two Partnership Projects
-
PlacementTracker Publishes 2017 PIPE and Private Placement Markets League Tables
-
Deerfield Continues its Commitment to Advancing Healthcare Through its Publication Activities
-
Braeburn Announces Completion of $110 Million Financing
-
Concert Genetics Completes Growth Financing
-
DFB Healthcare Acquisitions Corp. Files Registration Statement for Initial Public Offering of Securities
-
Quartet Kicks Off 2018 with $40 Million More in Funding and Three Industry Leaders Join the Board
-
CORRECTING and REPLACING Quartet Kicks Off 2018 with $40 Million More in Funding and Three Industry Leaders Join the Board
-
Bluefield Innovations Pursues Broadly Applicable Cancer Target
-
Horizon Technology Finance Provides $12 Million Venture Loan to Conventus Orthopaedics
-
Deerfield Discovers Gender Affects Treatment and Outcome in Abdominal Aortic Aneurysms
-
Fractyl Completes $44 Million Series D Financing to Advance New Treatment for Type 2 Diabetes
-
Deerfield Supports Melinta Therapeutics Acquisition of The Medicines Company's Infectious Disease Business with a $240 million Commitment to Melinta and a $100 million Commitment to The Medicines Comp
-
Melinta Therapeutics (MLNT) Announces Acquisition of Infectious Disease Business from The Medicines Company (MDCO)
-
Medicines Co. (MDCO) to Sell its Infectious Disease Business Unit to Melinta Therapeutics (MLNT) for $270M
-
The Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta Therapeutics
-
Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company
-
Deerfield and The Johns Hopkins University Announce Collaboration to Catalyze Early Stage Therapeutic Research

